SoftOx Solutions AS (SoftOx), a clinical-stage biopharmaceutical company based
in Norway, announces the completion of last subject last visit in a Phase 1
study of SIS-01 (NCT05188638). SIS-01 is a first-in-human study investigating
the safety and tolerability of single and multiple doses of nebulised SoftOx
Inhalation Solution (SIS) delivered via a jet nebuliser to healthy subjects. A
total of 57 healthy volunteers were randomised to receive SIS or placebo. SoftOx
is looking forward to announcing the top line results by the end of Q2 2022.

"We are pleased to report the achievement of this import milestone. We are
extremely grateful to our study participants and DanTrials ApS for helping us to
complete the study according to plan," said Dr Christopher Burton, Chief Medical
Officer on the SIS project. "We anticipate that this study will provide evidence
of a safety and tolerability profile suitable for progression to Phase 2
clinical development within various upper and lower respiratory tract infectious
disease indications."

SIS is a novel aqueous formulation of hypochlorous acid (HOCl), a biological
oxidant with broad spectrum antimicrobial (antiviral and antibacterial)
properties. This randomized, double-blind trial is the first systematic,
placebo-controlled, ascending dose study investigating the safety and
tolerability of low concentrations of inhaled HOCl in humans. 

For further information, please contact:
Geir Almås, CEO of SoftOx Solutions AS, or
Christopher Burton, CMO, SIS, SoftOx Solutions AS
Mail: ir@soft-ox.com
Phone: Front Desk: (+47) 948-59-599

About SoftOx Solutions AS
SoftOx Solutions AS (SoftOx, listed on Euronext Growth Oslo) is a Norwegian
biotech/medtech company based in Oslo with the aim of helping to combat major
threats to human health, namely the emergence of antimicrobial resistance (AMR),
biofilm infections in chronic wounds and the spread of viruses. For more
information on SoftOx, visit www.soft-ox.com